Loratadine versus cetirizine: Assessment of somnolence and motivation during the workday

Clinical Therapeutics

Volumn 22, Issue 5, 2000, Pages 573-582

  Salmun, Luis M ^a   Gates, Davis ^a   Scharf, Martin ^b   Greiding, Leonardo ^c   Ramon, Fabian ^d   Heithoff, Kim ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Ctr for Research in Sleep Disorders   (United States)

^c Instituto Argentina de Alergia e I   (Argentina)

^d Instituto de Alergia e Immunologia   (Argentina)

Author keywords

Allergic rhinitis; Antihistamine; Cetirizine; Loratadine; Somnolence

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; LORATADINE;

ADULT; ALLERGIC RHINITIS; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; NEUROTOXICITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SOMNOLENCE; TIME; TINNITUS; XEROSTOMIA;

EID: 0033919876     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80045-4     Document Type: Article

References (31)

1. 1. Ash ASF, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol. 1966;27:427-439.
2. 2. Barbee RA, Halonen M, Kaltenborn WT, Burrows B. A longitudinal study of respiratory symptoms in a community population sample. Correlations with smoking, allergen skin-test reactivity, and serum IgE. Chest. 1991;99:20-26.
3. 3. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol. 1999;103:401-407.
4. 4. Fireman P. Treatment of allergic rhinitis: Effect on occupation productivity and work force costs. Allergy Asthma Proc. 1997;18:63-67.
5. 5. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy. 1994; 73:35-39.
6. 6. Carruthers SG, Shoeman DW, Hignite CE, Azarnoff DC. Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther. 1978;23:375-382.
7. 7. Mattila MJ, Mattila M, Konno K. Acute and subacute actions on human performance and interactions with diazepam of temelastine (SK&F93944) and diphenhydramine. Eur J Clin Pharmacol. 1986;31:291-298.
8. 8. Gengo F, Gabos C, Miller JK. The pharmacodynamics of diphenhydramine-induced drowsiness and changes in mental performance. Clin Pharmacol Ther. 1989;45: 15-21.
9. 9. Kay GG, Berman B, Mockoviak SH, et al. Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood and psychomotor performance. Arch Intern Med. 1997;157:2350-2356.
10. 10. Cockburn LM, Bailit HL, Berndt ER, Finkelstein SN. Loss of work productivity due to illness and medical treatment. J Occup Environ Med. 1999;41:948-953.
11. 11. Monti JE. Involvement of histamine in the control of the waking state. Life Sci. 1993;53:1331-1338.
12. 1 receptor activation reduces a background leakage potassium current. Neuroscience. 1994;59:579-588.
13. 13. Sorkin EM, Heel RC. Terfenadine: A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985;29: 34-56.
14. 14. Krstenansky PM, Cluxton RJ Jr. Astemizole: A long-acting, nonsedating antihistamine. Drug Intell Clin Pharm. 1987; 21:947-953.
15. 15. Simons FER, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med. 1994;330:1663-1670.
16. 16. Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: A comparative review. Drugs. 1999;57:31-47.
17. 17. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994;48:617-637.
18. 18. Hilbert J, Radwanski E, Weglein R, et al. Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol. 1987; 27:694-698.
19. 19. Radwanski E, Hilbert J, Symchowicz S, Zampaglione N. Loratadine: Multiple-dose pharmacokinetics. J Clin Pharmacol 1987;27:530-533.
20. 20. Barnett A, Iorio LC, Kreutner W, et al. Evaluation of the CNS properties of SCH 29851, a potent non-sedating antihistamine. Agents Actions. 1984;14:590-597.
21. 21. Ahn H-S, Barnett A. Selective displacement of [3H]mepyramine from peripheral vs. central nervous system receptors by loratadine, a non-sedating antihistamine. Eur J Pharmacol. 1986;127:153-155.
22. 22. Bradley CM, Nicholson AN. Studies on the central effects of the H1-antagonist, loratadine. Eur J Clin Pharmacol. 1987; 32:419-421.
23. 23. Gaillard AW, Gruisen A, de Jong R. The influence of antihistamines on human performance. Eur J Clin Pharmacol. 1988; 35:249-253.
24. 24. Ramaekers JG, Uiterwijk MM, O'Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol. 1992;42:363-369.
25. 25. Falliers CJ, Brandon ML, Buchman E, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy. 1991;66:257-262.
26. 26. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999; 104:927-933.
27. 27. Walsh JK, Muehlbach MJ, Schweitzer PK. Simulated assembly line performance following ingestion of cetirizine or hydoxyzine. Ann Allergy. 1992;69:195-200.
28. 1-antihistamine, cetirizine. Aviat Space Environ Med. 1998;69:166-171.
29. 29. Spencer CM, Faulds D, Peters DH. Cetirizine. A reappraisal of its pharmacological properties and potential in allergic rhinitis, pollen-induced asthma and chronic urticaria. Drugs. 1993;40:762-781.
30. 30. Pechadre JC, Beudin P, Eschalier A, et al. A comparison of central and peripheral effects of cetirizine and loratadine. J Int Med Res. 1991;19:289-295.
31. 31. Mattila MJ, Paakkari I. Variations among non-sedating antihistamines: Are there real differences? Eur J Clin Pharmacol. 1999;55:85-93.